Published in World J Gastroenterol on August 28, 2006
Clearing the smoke in chronic liver diseases. Hepatology (2010) 1.17
Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J Gastroenterol (2011) 1.05
Active smoking, passive smoking, and risk of nonalcoholic fatty liver disease (NAFLD): a population-based study in China. J Epidemiol (2013) 0.90
A cross-sectional investigation of chronic exposure to microcystin in relationship to childhood liver damage in the Three Gorges Reservoir Region, China. Environ Health Perspect (2011) 0.87
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature (1997) 10.53
Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest (1995) 9.59
The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology (2002) 5.70
Regional adiposity and morbidity. Physiol Rev (1994) 3.85
Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology (1990) 3.63
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol (2005) 3.18
Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab (2004) 2.74
Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab (2003) 2.56
Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol (2005) 2.46
Hepatic steatosis: innocent bystander or guilty party? Hepatology (1998) 1.94
Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology (2001) 1.51
Smoking and incidence of diabetes among U.S. adults: findings from the Insulin Resistance Atherosclerosis Study. Diabetes Care (2005) 1.48
Do measures of body fat distribution provide information on the risk of type 2 diabetes in addition to measures of general obesity? Comparison of anthropometric predictors of type 2 diabetes in Pima Indians. Diabetes Care (2003) 1.44
The influence of obesity and gestational diabetes mellitus on accretion and the distribution of adipose tissue in pregnancy. Am J Obstet Gynecol (2003) 1.30
Impact of obesity and body fat distribution on cardiovascular risk factors in Hong Kong Chinese. Obes Res (2004) 1.26
Side-stream cigarette smoke induces dose-response in systemic inflammatory cytokine production and oxidative stress. Exp Biol Med (Maywood) (2002) 1.16
Smoking and liver cancer in China: case-control comparison of 36,000 liver cancer deaths vs. 17,000 cirrhosis deaths. Int J Cancer (2003) 1.15
Smoking as a risk factor for visceral fat accumulation in Japanese men. Tohoku J Exp Med (2006) 1.11
The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease. Eur J Epidemiol (1994) 1.08
Smoking is associated with increased hepatic lipase activity, insulin resistance, dyslipidaemia and early atherosclerosis in Type 2 diabetes. Atherosclerosis (2001) 1.06
Associations between smoking and beta-cell function in a non-hypertensive and non-diabetic population. Skaraborg Hypertension and Diabetes Project. Diabet Med (2000) 1.00
Fat distribution in relation to age, degree of obesity, smoking habits, parity and estrogen use: a cross-sectional study in 11,825 Dutch women participating in the DOM-project. Int J Obes (1990) 0.98
Relationship between smoking habits and the features of the metabolic syndrome in a non-diabetic population. Nutr Metab Cardiovasc Dis (2005) 0.96
Endocrine effects of tobacco smoking. Clin Endocrinol (Oxf) (2004) 0.92
Smokeless tobacco impairs the antioxidant defense in liver, lung, and kidney of rats. Toxicol Sci (2005) 0.90
[An update on non-alcoholic fatty liver disease]. Rev Invest Clin (2004) 0.82
Alteration of cytochrome P-450 and glutathione S-transferase activity in normal and malignant human stomach. J Toxicol Environ Health A (2005) 0.80
Lifecourse predictors of normal metabolic parameters in overweight and obese adults. Int J Obes (Lond) (2006) 0.79
Effects of cigarette smoke with different tar contents on hepatic and pulmonary xenobiotic metabolizing enzymes in rats. Hum Exp Toxicol (2002) 0.79
[Obesity and non-alcoholic steatohepatitis]. Gac Med Mex (2005) 0.78
Effects of different exposure times to tobacco smoke intoxication on carboxyhemoglobin and hepatic enzymate activities in mice. J Pharmacol Toxicol Methods (1996) 0.77
[Health risk from active and passive smoking]. Rev Esp Salud Publica (2003) 0.77
Strong association between gallstones and cardiovascular disease. Am J Gastroenterol (2005) 2.43
Metabolic syndrome as a risk factor for gallstone disease. World J Gastroenterol (2005) 1.49
High ghrelin and obestatin levels and low risk of developing fatty liver. Ann Hepatol (2010) 1.47
Diagnostic value of the copper/zinc ratio in hepatocellular carcinoma: a case control study. J Gastroenterol (2003) 1.45
Hepatic apolipoprotein A-I gene expression in patients with cholesterol gallstones treated with ursodeoxycholic acid. Ann Hepatol (2004) 1.40
Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev (2010) 1.38
Hepatocellular carcinoma. An overview. Ann Hepatol (2006) 1.29
The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology (2013) 1.27
Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int (2007) 1.24
Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol (2010) 1.21
Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology (2008) 1.16
Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev (2010) 1.12
Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma. BMC Cancer (2005) 1.11
Image-guided percutaneous procedure plus metronidazole versus metronidazole alone for uncomplicated amoebic liver abscess. Cochrane Database Syst Rev (2009) 1.09
Endoscopic submucosal dissection in dogs in a World Gastroenterology Organisation training center. World J Gastroenterol (2010) 1.04
Liver involvement in severe human influenza a H1N1. Ann Hepatol (2010) 1.01
Anabolic-androgenic steroids and liver injury. Liver Int (2007) 1.00
Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. J Hepatol (2007) 1.00
High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Ann Hepatol (2012) 0.97
Hepatic manifestations of Epstein-Barr viral infection. Ann Hepatol (2005) 0.96
Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. Ann Hepatol (2008) 0.94
Eosinophilic gastroenteritis: a review. Dig Dis Sci (2007) 0.94
Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol (2006) 0.93
Role of diet in cholesterol gallstone formation. Clin Chim Acta (2006) 0.93
Learning curve in a Western training center of the circumferential en bloc esophageal endoscopic submucosal dissection in an in vivo animal model. Diagn Ther Endosc (2011) 0.93
Association among C-reactive protein, Fatty liver disease, and cardiovascular risk. Dig Dis Sci (2007) 0.92
Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol (2008) 0.92
Association between cholecystectomy for gallstone disease and risk factors for cardiovascular disease. Ann Hepatol (2011) 0.90
Hepatic encephalopathy: a review. Ann Hepatol (2004) 0.90
Etiology of liver cirrhosis in Mexico. Ann Hepatol (2004) 0.90
Pregnancy and gallbladder disease. Ann Hepatol (2006) 0.90
Hepatobiliary diseases in patients with human immunodeficiency virus (HIV) treated with non highly active anti-retroviral therapy: frequency and clinical manifestations. Ann Hepatol (2005) 0.89
Treating nonalcoholic fatty liver disease. Liver Int (2007) 0.89
Gallstones are associated with carotid atherosclerosis. Liver Int (2007) 0.89
Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjögren's syndrome. Ann Hepatol (2007) 0.88
Prevalence of minimal hepatic encephalopathy and quality of life in patients with decompensated cirrhosis. Hepatol Res (2013) 0.88
Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol (2005) 0.87
Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. Ann Hepatol (2004) 0.86
Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico. J Clin Microbiol (2004) 0.85
Hepatocellular carcinoma in Hispanics. Ann Hepatol (2007) 0.85
In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: Correlation with biochemical method and morphometry. J Hepatol (2010) 0.85
Zinc sulfate inhibits the enterohepatic cycling of unconjugated bilirubin in subjects with Gilbert's syndrome. Ann Hepatol (2004) 0.83
Prophylactic activated recombinant factor VII in liver resection and liver transplantation: systematic review and meta-analysis. PLoS One (2011) 0.82
[An update on non-alcoholic fatty liver disease]. Rev Invest Clin (2004) 0.82
Sorafenib, a systemic therapy for hepatocellular carcinoma. Ann Hepatol (2008) 0.82
Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review. World J Gastroenterol (2006) 0.82
IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFNα 2b and ribavirin in patients with hepatitis C virus genotype 1. Arch Med Res (2011) 0.82
Prevalence of hepatitis C infection in a population of asymptomatic people in a checkup unit in Mexico city. Dig Dis Sci (2005) 0.82
Transcript levels of Toll-Like Receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis. BMC Gastroenterol (2011) 0.82
Microscopic colitides: a single center experience in Mexico. Int J Colorectal Dis (2007) 0.82
Biliary stricture caused by portal biliopathy: case report and literature review. Ann Hepatol (2006) 0.82
Plasma leptin and the cholesterol saturation of bile are correlated in obese women after weight loss. J Nutr (2002) 0.82
Autoimmune hepatitis with giant-cell transformation. Ann Hepatol (2009) 0.82
The Amerindian's genes in the Mexican population are associated with development of gallstone disease. Am J Gastroenterol (2004) 0.82
TLR9 mRNA expression is upregulated in patients with active ulcerative colitis. Inflamm Bowel Dis (2010) 0.82
Alcoholic liver disease. An update. Ann Hepatol (2005) 0.81
Acute liver failure and the Molecular Adsorbents Recirculating System: early experience in a tertiary care hospital in Mexico City. Ann Hepatol (2005) 0.81
Prevalence of type 2 diabetes mellitus and chronic liver disease: a retrospective study of the association of two increasingly common diseases in Mexico. Ann Hepatol (2010) 0.81
Common features of the metabolic syndrome and nonalcoholic fatty liver disease. Rev Recent Clin Trials (2014) 0.81
Worldwide mortality from cirrhosis. Ann Hepatol (2007) 0.81
The role of dietary fats in the pathogenesis of gallstones. Front Biosci (2003) 0.81
[New molecular features of cholestatic diseases of the liver]. Rev Invest Clin (2004) 0.80
The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med (2006) 0.80
Clinical course and management of acute hepatitis A infection in adults. Ann Hepatol (2012) 0.80
Association between serum concentration of apolipoproteins A-I and B with gallbladder disease. Arch Med Res (2003) 0.80
Albumin dialysis with molecular adsorbent recirculating system (MARS) for the treatment of hepatic encephalopathy in liver failure. Ann Hepatol (2011) 0.80
Risk factors and prevalence of hepatitis virus B and C serum markers among nurses at a tertiary-care hospital in Mexico City, Mexico: a descriptive study. Ann Hepatol (2006) 0.80
Does HLA-DR7 differentiate the overlap syndrome of auto-immune hepatitis-primary biliary cirrhosis (AIH-PBC) from those with auto-immune hepatitis type 1? Ann Hepatol (2011) 0.80
High gene expression of MDR1 (ABCB1) is associated with medical treatment response and long-term remission in patients with ulcerative colitis. Inflamm Bowel Dis (2010) 0.80
Adiponectin as a protective factor in hepatic steatosis. World J Gastroenterol (2005) 0.79
Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal states. Ann Hepatol (2010) 0.79
Metabolic syndrome and nonalcoholic fatty liver disease. The role of endothelial progenitor cells. Ann Hepatol (2013) 0.79
Coagulation abnormalities in the cirrhotic patient. Ann Hepatol (2013) 0.79
Intestinal flora, probiotics, and cirrhosis. Ann Hepatol (2008) 0.79
Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population. Ann Hepatol (2013) 0.79
Non-alcoholic fatty-liver disease in pediatric populations. J Pediatr Endocrinol Metab (2007) 0.79
Pathophysiology of ascites and dilutional hyponatremia: contemporary use of aquaretic agents. Ann Hepatol (2007) 0.79
Effect of Helicobacter pylori infection on gastric ghrelin expression and body weight. Rev Gastroenterol Mex (2008) 0.79
[Gallbladder disease and obesity]. Gac Med Mex (2005) 0.79
The molecular basis of susceptibility to infection in liver cirrhosis. Curr Med Chem (2007) 0.78
Hepatic manifestations of metabolic syndrome. Diabetes Metab Res Rev (2013) 0.78
Hepatobiliary diseases and insulin resistance. Curr Med Chem (2007) 0.78
A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr J (2013) 0.78
Human leukocyte antigens among primary biliary cirrhosis patients born in Mexico. Ann Hepatol (2009) 0.78
[Obesity and non-alcoholic steatohepatitis]. Gac Med Mex (2005) 0.78
Role of nonalcoholic fatty liver disease in hepatocellular carcinoma. Ann Hepatol (2009) 0.78
Mortality trends for liver cancer in Mexico from 2000 to 2006. Ann Hepatol (2008) 0.78
Nuclear receptors in nonalcoholic Fatty liver disease. J Lipids (2011) 0.78
Evaluation of iron overload in healthy adult residents of Mexico City. Arch Med Res (2005) 0.78
[National consensus on hepatitis C. Conclusions]. Rev Invest Clin (2003) 0.78
Acute kidney injury in critically ill cirrhotic patients: a review. Ann Hepatol (2012) 0.77
Pylephlebitis of portal venous system associated with urinary infection. Dig Dis Sci (2003) 0.77
Beta blockers in portal hypertension. Are they really a good option? Ann Hepatol (2006) 0.77
Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. Ann Hepatol (2010) 0.77
Alcohol effects on liver diseases: good or bad buddy?. Ann Hepatol (2012) 0.77
Serum leptin levels and insulin resistance are associated with gallstone disease in overweight subjects. World J Gastroenterol (2005) 0.76
The Role of Epigenetics in the Progression of Non-Alcoholic Fatty Liver Disease. Mini Rev Med Chem (2015) 0.76
The efficacy of adipokines and indices of metabolic syndrome as predictors of severe obesity-related hepatic steatosis. Dig Dis Sci (2006) 0.76
Biliverdin and heme oxygenase antiviral activity against hepatitis C virus. Ann Hepatol (2011) 0.76